semaglutide fda ruling faces new lawsuit from compounders over wight loss drugs FDA Approves Oral Semaglutide for
Description
GLP-1 medications, by contrast, actively reduce cardiovascular risk
The retrospective design, absence of a comparator group, and potential confounding from concurrent therapies limit causal inference
Some reports of chest pain have been recorded in people using semaglutide, but they are not frequent enough to show a clear pattern
Sandberg, L
A few prefilled syringes in a small insulated case
